Merck & Co., Inc. (NYSE:MRK) Shares Sold by Norinchukin Bank The

Norinchukin Bank The lessened its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.8% in the 4th quarter, Holdings Channel reports. The fund owned 242,453 shares of the company’s stock after selling 4,497 shares during the period. Norinchukin Bank The’s holdings in Merck & Co., Inc. were worth $18,582,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of MRK. Financial Avengers Inc. boosted its position in shares of Merck & Co., Inc. by 115.8% in the fourth quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after acquiring an additional 176 shares during the period. Moisand Fitzgerald Tamayo LLC raised its position in shares of Merck & Co., Inc. by 78.0% during the fourth quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock worth $27,000 after acquiring an additional 156 shares during the last quarter. Retirement Group LLC increased its stake in Merck & Co., Inc. by 116.4% in the third quarter. Retirement Group LLC now owns 608 shares of the company’s stock valued at $30,000 after purchasing an additional 327 shares in the last quarter. Bellwether Advisors LLC boosted its holdings in Merck & Co., Inc. by 460.0% during the third quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock worth $31,000 after purchasing an additional 345 shares during the last quarter. Finally, Steward Financial Group LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 72.88% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 price objective on the stock. Barclays upped their price target on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. StockNews.com began coverage on Merck & Co., Inc. in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Morgan Stanley decreased their target price on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Finally, JPMorgan Chase & Co. lowered their price target on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating on the stock in a report on Friday, January 28th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $90.69.

Shares of MRK stock traded up $1.64 during trading hours on Thursday, reaching $90.83. The company’s stock had a trading volume of 14,008,381 shares, compared to its average volume of 12,199,652. The firm’s 50 day simple moving average is $83.71 and its 200-day simple moving average is $80.64. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $91.40. The company has a quick ratio of 1.02, a current ratio of 1.27 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $229.69 billion, a price-to-earnings ratio of 16.25, a PEG ratio of 1.19 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.31. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The company had revenue of $15.90 billion during the quarter, compared to analyst estimates of $14.64 billion. During the same period in the prior year, the business posted $1.40 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 31.6% on a year-over-year basis. Sell-side analysts predict that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.